Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that finasteride undergoes second-order alkaline degradation kinetics and that its degraded form negatively impacts cell proliferation, highlighting the need for careful handling in pharmaceutical manufacturing and storage.

In this study, complexation with cyclodextrins was reported to increase the solubility of FIN for potential use in aqueous formulations for treating male androgenic alopecia.

This study found that two eco-friendly analytical methods for quantifying Finasteride and Tadalafil in a new dosage form were effective, green, and suitable for quality control.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study developed and validated a second derivative spectrophotometric method for accurately estimating tamsulosin and finasteride in bulk and pharmaceutical formulations.

This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.

This study validated a new RP-HPLC method for accurately determining doxazosin mesylate and finasteride in bulk powders and capsule formulations.

This research emphasizes the importance of integrating pre-treatment psychological assessments for individuals considering finasteride, highlighting that these assessments could help identify those prone to nocebo responses, potentially reducing adverse symptom development more related to cognitive vulnerabilities than to the drug itself.

This study explored a novel finasteride-loaded nanoparticle gel for treating alopecia areata, finding that it significantly increased hair follicle number and size without causing skin irritation, presenting an effective alternative to traditional minoxidil treatments.

This study proposes that combining trazodone and clomiphene citrate could potentially restore libido synaptic circuits and treat post-finasteride syndrome, which involves persistent sexual dysfunction after discontinuing finasteride treatment.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

This study found that poly(propylene carbonate maleate) microspheres can successfully prolong finasteride release over 42 days, showing potential for long-term sustained drug delivery.

This study reported that invasomes, utilizing limonene as a component, enhanced the transdermal permeation of finasteride by over 21 times, indicating their potential as a novel drug delivery system.

The abstract reports no new clinical results; it describes finasteride’s mechanism of action in androgenetic alopecia and mentions unpublished trial results by the manufacturer and investigators.

PRP therapy can regrow 30%-40% of lost hair in 3 months without side effects.

This study observed hair regrowth and increased density in four cases of androgenetic alopecia treated with a non-ablative erbium glass fractional laser and topical finasteride, with no significant side effects reported.

This abstract mentions that while synthetic drugs like minoxidil and finasteride for androgenic alopecia have side effects, the characteristics of popular natural alternatives, such as soybean, remain largely unreported, despite consumer preference for these products.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This review discusses ethosomes as lipid carriers that enhance drug penetration into deep skin layers and underscores the need for advanced research on their pharmaceutical applications, but it reports no clinical outcomes.

This study found that Shi-Bi-Man, a hair health supplement, significantly promoted hair growth in mice, likely through activation of the FGF signaling pathway.

This review discusses advancements in managing male androgenetic alopecia, emphasizing long-term restoration techniques like follicular unit grafting combined with medical treatments, and reports no new experimental findings.

This article discusses surgical hair restoration using micrografting techniques, emphasizing its ability to produce natural-looking results without the "hair plug" appearance, and reports no new clinical findings.

This study demonstrated that CD anisotropy effectively distinguishes between two polymorphs of finasteride with nearly identical electronic circular dichroism spectra, using imaging and simulated spectra to uncover unique signatures that traditional methods miss.

This study discusses the limitations of current FDA-approved treatments for androgenic alopecia, noting significant sexual side effects with oral finasteride and formulation challenges with topical minoxidil, and highlights the potential of nanocarriers to improve drug delivery to hair follicles.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

Using a mix of finasteride and minoxidil can significantly regrow hair in men with pattern baldness.

In this study, petroleum ether extract of Citrullus colocynthis fruit effectively promoted hair growth in a mouse model of androgen-induced alopecia, showing comparable results to the standard treatment, finasteride.

This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.